Menlo Park, CA, United States of America

Paul A Wender

USPTO Granted Patents = 37 (Patent Applications = 12)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.5

ph-index = 12

Forward Citations = 907(Granted Patents)

Location History:

Menlo Park, CA (US) (2001 - 2021)
Stanford, CA (US) (2021 - 2023)
Palo Alto, CA (US) (2014 - 2024)

Company Filing History:

29 out of 5,303

Leland Stanford Junior University

Kai Pharmaceuticals, Inc.

patents

4. 1 out of 164,108

International Business Machines Corporation

patents

5. 1 out of 15,458

University of California

patents

where one patent can have more than one assignee

Years Active: 2001-2025

where 'Filed Patents' based on already Granted Patents

37 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12435071 - Bryostatin compounds and methods of preparing the same (2025-10-07),

2. 12215341 - Hybrid immolative cell-penetrating complexes for nucleic acid delivery (2025-02-04),

3. 12194105 - Composition and method for new antimicrobial agents with secondary mode of action provided by conjugation of an antimicrobial to a guanidinium-rich molecular transporter (2025-01-14),

4. 11931416 - Immolative cell-penetrating complexes for nucleic acid delivery to the lung (2024-03-19),

5. 11746105 - Bryostatin compounds and methods of preparing the same (2023-09-05),

6. 11370743 - Prodrug derivatives of protein kinase C modulators (2022-06-28),

7. 10961263 - Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery (2021-03-30),

8. 10947221 - Bryostatin compounds and methods of preparing the same (2021-03-16),

9. 10654875 - Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery (2020-05-19),

10. 9902957 - Amphipathic co-oligomers for the delivery of siRNA (2018-02-27),

11. 9816066 - Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters (2017-11-14),

12. 8816122 - Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use (2014-08-26),

13. 8795734 - Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells (2014-08-05),

14. 8735609 - Bryostatin analogues, synthetic methods and uses (2014-05-27),

15. 8729010 - Compositions and methods for enhancing drug delivery across and into ocular tissues (2014-05-20),

Title: The Legacy of Paul A. Wender: Innovating Chemistry and Pharmaceuticals

Introduction:

Paul A. Wender, a visionary inventor in the field of chemistry and pharmaceuticals, has dedicated his career to pushing the boundaries of scientific innovation. His pioneering spirit and relentless pursuit of excellence have cemented his legacy as a true luminary in the industry.

Latest Patents:

With an impressive portfolio of 33 patents to his name, Paul A. Wender continues to make significant contributions to the field. Among his latest patents is the groundbreaking work on Bryostatin compounds and methods of preparing the same. These methods provide for the preparation of bryostatin 1 in multi-gram quantities in a low number of convergent synthetic steps, making them scalable and cost-effective for meeting clinical needs. Additionally, his work on prodrug derivatives of protein kinase C modulators showcases his commitment to developing innovative therapeutic agents with improved efficacy and stability.

Career Highlights:

Throughout his illustrious career, Paul A. Wender has held key positions at renowned institutions such as Leland Stanford Junior University and Cellgate, Inc. His expertise and leadership have been instrumental in shaping the field of chemistry and pharmaceuticals, inspiring countless aspiring inventors to push the boundaries of scientific knowledge.

Collaborations:

Paul A. Wender has collaborated with esteemed colleagues such as Jonathan B. Rothbard and Lalitha V. S. Sista, leveraging their collective expertise to advance the frontiers of research in chemistry and pharmaceuticals. Together, they have made significant strides in developing novel compounds and prodrug formulations that hold great promise for academic research and therapeutic applications.

Conclusion:

In conclusion, Paul A. Wender's unwavering dedication to scientific innovation, coupled with his outstanding contributions to the field of chemistry and pharmaceuticals, firmly establishes him as a trailblazing inventor of our time. His visionary approach and collaborative spirit serve as a beacon of inspiration for future generations of inventors and innovators seeking to make a profound impact on the world of science.

This text is generated by artificial intelligence and may not be accurate.